FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1	OMB APPRO	VAL							
	OMB Number:	3235-0287							
	Estimated average burden								
	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  YINGLING JONATHAN MICHAEL					2. Issuer Name <b>and</b> Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC. 167 SIDNEY STREET				0	1/03/2	2018		saction (Mont			X Officer (give title Other (specify below)  SVP, Early Development					
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4.								ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person				
		Ta	ble I - Non-Do	erivati	ve Se	ecurities	s Ac	quired, D	isposed o	f, or Be	neficially	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					saction ZA. Deemed Execution Date if any (Month/Day/Year)			Code (Instr.			ed (A) or tr. 3, 4 and 5	Beneficia Owned Fe	s For ally (D) following (I) (		: Direct   I Indirect   E str. 4)   (	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) o (D)	Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) f tive	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(	i ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	vii(ə)		
Stock Option	\$2.24	01/03/2018		A		270,000		(1)	01/03/2028	Common Stock	270,000	\$2.24	270,00	0	D	

## **Explanation of Responses:**

1. This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant.

/s/Jonathan Yingling

01/05/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.